NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large ischemic strokes will be presented during two oral presentations at the upcoming International Stroke Conference (ISC) 2016, being held February 17-19, 2016 at the Los Angeles Convention Center in Los Angeles, California.
The two oral presentations will be conducted by principal investigators and leading neuroscience researchers at Yale University and Massachusetts General Hospital.
“We are thrilled to have this exciting data presented to a group of illustrious clinicians at the world’s largest and most prestigious medical meeting dedicated to the science and treatment of cerebrovascular disease,” commented Sven Jacobson, CEO of Remedy Pharmaceuticals. “Edema is one of the most significant mortality risks associated with stroke and other acute CNS conditions. In fact, in the first week following an ischemic stroke, 78% of all deaths are attributable to edema and in hemorrhagic stroke, 93% of deaths are caused by this type of swelling. CNS edema continues to be a condition characterized by major unmet medical need. We look forward to sharing the full results of the Phase 2 trial evaluating CIRARA for reduction of the devastating consequences associated with edema after a severe stroke.”
Read More: https://beta.finance.yahoo.com/news/remedy-pharmaceuticals-announces-acceptance-two-143556262.html
Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA™ for CNS-Related Edema at ISC 2016
Via: Yahoo! Finance